Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA4 | P22748 | 1/20 | 0.50 |
| ▸ | KIF11 | P52732 | 9/20 | 0.49 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.49 |
| ▸ | LTA4H | P09960 | 2/20 | 0.48 |
| ▸ | CA1 | P00915 | 2/20 | 0.44 |
| ▸ | CA2 | P00918 | 2/20 | 0.44 |
| ▸ | CA12 | O43570 | 1/20 | 0.44 |
| ▸ | CA7 | P43166 | 1/20 | 0.44 |
| ▸ | CA9 | Q16790 | 1/20 | 0.44 |
| ▸ | CA14 | Q9ULX7 | 1/20 | 0.44 |
| ▸ | TRPA1 | O75762 | 1/20 | 0.44 |
| ▸ | CES2 | O00748 | 1/20 | 0.41 |
| ▸ | CES1 | P23141 | 1/20 | 0.41 |
| ▸ | NPC1 | O15118 | 1/20 | 0.40 |
| ▸ | RAB9A | P51151 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3932304 | 1.00 | CA4 (0.50) | CA4KIF11KCNH2LTA4HCA1 | |
| SCHEMBL6546972 | 0.92 | CA1 (0.52) | CA4LTA4HCA1CA2CA12 | |
| SCHEMBL434969 | 0.83 | CA4 (0.54) | CA4KIF11KCNH2LTA4HCA1 | |
| SCHEMBL136229 | 0.83 | CA4 (0.54) | CA4KIF11KCNH2LTA4HCA1 | |
| SCHEMBL8784660 | 0.83 | CA4 (0.54) | CA4KIF11KCNH2LTA4HCA1 | |
| SCHEMBL774134 | 0.83 | CA4 (0.54) | CA4KIF11KCNH2LTA4HCA1 | |
| SCHEMBL328834 | 0.82 | KIF11 (0.44) | KIF11 | |
| Hydrochloric Acid SCHEMBL30389842 | 0.82 | CA4 (0.52) | CA4KIF11KCNH2LTA4HCA1 | |
| Bromide SCHEMBL31164184 | 0.82 | CA4 (0.52) | CA4KIF11KCNH2LTA4HCA1 | |
| SCHEMBL8728589 | 0.80 | KIF11 (0.56) | CA4KIF11KCNH2LTA4HCA1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 30 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20030129589-A1 | DNA DIAGNOSTICS BASED ON MASS SPECTROMETRY | SEQUENOM, INC. | 2003-07-10 | — | — | US | claimed |
| US-20020042112-A1 | DNA DIAGNOSTICS BASED ON MASS SPECTROMETRY | SEQUENOM, INC. | 2002-04-11 | — | — | US | claimed |
| EP-0954612-A2 | DNA DIAGNOSTICS BASED ON MASS SPECTROMETRY | SEQUENOM, INC. (US) | 1999-11-10 | — | — | EP | claimed |
| WO-1998020166-A2 | DNA DIAGNOSTICS BASED ON MASS SPECTROMETRY | SEQUENOM, INC. (US) | 1998-05-14 | — | — | WO | claimed |
| EP-1457496-B1 | High density immobilization of nucleic acids | SEQUENOM INC (US) | 2014-01-15 | — | — | EP | disclosed |
| EP-1296143-B1 | Mass spectrometric detection of polypeptides | SEQUENOM INC (US) | 2009-06-03 | — | — | EP | disclosed |
| US-7501251-B2 | DNA diagnostics based on mass spectrometry | SEQUENOM, INC. (US) | 2009-03-10 | — | — | US | disclosed |
| US-20090023150-A1 | DNA Diagnostics Based on Mass Spectrometry | SEQUENOM, INC. (US) | 2009-01-22 | — | — | US | disclosed |
| EP-1164203-B1 | DNA Diagnostics based on mass spectrometry | SEQUENOM INC (US) | 2007-10-10 | — | — | EP | disclosed |
| US-20070202514-A1 | DNA diagnostics based on mass spectrometry | SEQUENOM, INC. (US) | 2007-08-30 | — | — | US | disclosed |
| US-7198893-B1 | DNA diagnostics based on mass spectrometry | SEQUENOM, INC. (US) | 2007-04-03 | — | — | US | disclosed |
| EP-1010008-B1 | MASS SPECTROMETRIC DETECTION OF POLYPEPTIDES | SEQUENOM INC (US) | 2006-11-22 | — | — | EP | disclosed |
| EP-1164203-A2 | DNA Diagnostics based on mass spectrometry | SEQUENOM, INC. (US) | 2001-12-19 | — | — | EP | disclosed |
| US-6322970-B1 | DIAGNOSING GENETIC OR CHROMOSOMAL DISORDERS; IN VITRO TRANSCRIPTION AND TRANSLATION; SEQUENCE DETERMINATION | SEQUENOM, INC. | 2001-11-27 | — | — | US | disclosed |
| EP-1010008-A2 | MASS SPECTROMETRIC DETECTION OF POLYPEPTIDES | SEQUENOM, INC. (US) | 2000-06-21 | — | — | EP | disclosed |
| EP-0954612-A2 | DNA DIAGNOSTICS BASED ON MASS SPECTROMETRY | SEQUENOM, INC. (US) | 1999-11-10 | — | — | EP | disclosed |
| EP-0937096-A2 | HIGH DENSITY IMMOBILIZATION OF NUCLEIC ACIDS | SEQUENOM, INC. (US) | 1999-08-25 | — | — | EP | disclosed |
| WO-1999012040-A2 | MASS SPECTROMETRIC DETECTION OF POLYPEPTIDES | SEQUENOM, INC. (US) | 1999-03-11 | — | — | WO | disclosed |
| WO-1998020166-A2 | DNA DIAGNOSTICS BASED ON MASS SPECTROMETRY | SEQUENOM, INC. (US) | 1998-05-14 | — | — | WO | disclosed |
| WO-1998020020-A2 | HIGH DENSITY IMMOBILIZATION OF NUCLEIC ACIDS | SEQUENOM, INC. (US) | 1998-05-14 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020042112-A1 | DNA DIAGNOSTICS BASED ON MASS SPECTROMETRY | DNA2, DDB1, DNMT3A | CA4 2001/4885KIF11 1143/4885KCNH2 3260/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.